Acute Myelomonocytic Leukemia (AMML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Acute Myelomonocytic Leukemia (AMML) Market Outlook

Thelansis’s “Acute Myelomonocytic Leukemia (AMML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Myelomonocytic Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Myelomonocytic Leukemia Overview

Acute myeloblastic leukemia (AML) is a type of cancer that affects the bone marrow and involves the malignant growth of myeloid precursors of white blood cells. Among pediatric cases of AML, acute myelomonocytic leukemia (AML-M4) is a frequently occurring subtype. The symptoms of AML can be non-specific and include weakness, paleness, fever, lightheadedness, and respiratory problems. However, more specific indicators of the disease include bleeding or bruising, coagulation disorders (DIC), neurological symptoms, and gingival hyperplasia. The exact cause of acute myelomonocytic leukemia AMML) is unknown. AMML represents 5-10% of all cases of AML. AMML occurs in all age groups but is a disease of older individuals (over 60 years). The median age of patients with AMML is 50 years. AMML is slightly more common in males, with a male-to-female ratio of 1.4. One chromosomal abnormality commonly seen in cases of AML-M4 is the inv(16) mutation. Children with AML-M4 who have the inv(16) mutation tend to have a better prognosis, with a 61% overall survival rate after five years.

• AMML is rare, represents approximately 3 % of all leukemias during childhood, and has an incidence of 1.1 – 1.7 cases per million per year.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: